Compositions comprising a polyphenolic extract stabilized in eutectic solvent (NADES) and resveratrol
A stabilized polyphenolic composition using olive oil extracts and resveratrol in a NaDES solvent addresses the limitations of current LSA treatments by providing anti-inflammatory and antioxidant effects, enhancing stability, and promoting tissue regeneration, thus improving treatment safety and efficacy.
Patent Information
- Application Number
- PCT/IB2026/054477
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for Lichen sclerosus et atrophicus (LSA) using corticosteroids and immunosuppressants are associated with side effects and recurrence of symptoms, while natural polyphenolic extracts can be harsh on the skin and unstable, reducing their therapeutic efficacy.
A composition comprising a eutectic solvent extract of polyphenols from olive oil, optionally with resveratrol, tocopherols, and phytosterols, stabilized by a natural deep eutectic solvent (NaDES), which provides anti-inflammatory, antioxidant, and skin barrier-protective effects, reducing the need for corticosteroids and improving stability.
The composition offers improved safety and efficacy in treating LSA by reducing skin irritation, enhancing stability, and promoting gradual absorption without interfering with mucosal lesions, while simultaneously modulating immune response and regenerating tissue.
Smart Images

Figure IMGF000023_0001_TABLE 
Figure 00000029_0000 
Figure 00000030_0000
Abstract
Description
[0001] COMPOSITIONS COMPRISING A POLYPHENOLIC EXTRACT STABILIZED IN EUTECTIC SOLVENT (NADES) AND RESVERATROL
[0002] DESCRIPTION
[0003] FIELD OF THE INVENTION
[0004] The present invention relates to the field of dermatology and refers to a composition comprising an extract of polyphenols and resveratrol in eutectic solvents. The invention also relates to the therapeutic applications of said composition, particularly in the treatment of Lichen Sclerosus et Atrophicus (LSA).
[0005] STATE OF THE ART
[0006] Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory condition, often associated with immune dysfunction, that primarily affects the skin and genital mucous membranes, causing itching, pain, burning, and anatomical changes. Currently available treatment strategies involve treating patients with this condition using corticosteroids, administered topically or systemically depending on the severity of the case, and / or immunosuppressants, primarily tacrolimus, cyclosporine, or methotrexate; however, these treatment methods are not without side effects: for example, although corticosteroids are the treatment of choice for managing local inflammation, prolonged use may be associated with adverse effects such as skin thinning, tachyphylaxis, and fungal infections; in addition, the recurrence of symptoms associated with LSA is common once corticosteroid therapy is discontinued. Furthermore, the use of immunosuppressants — indicated for resistant or particularly aggressive forms of LSA — in combination with topical corticosteroid treatments not only fails to guarantee prolonged remission in all patients but also carries systemic toxicity that requires constant clinical monitoring of treated individuals.
[0007] Recent clinical studies suggest a potential use of natural derivatives, such as extracts containing polyphenolic fractions (due to their antioxidant andimmunomodulatory properties), in the treatment of LSA. However, if not properly formulated, these extracts can be harsh on the skin, causing irritation or other side effects, which can sometimes slow down the healing process or even worsen existing irritation; furthermore, due to their limited stability, the clinical efficacy of these extracts may be reduced; in fact, polyphenols are susceptible to oxidative and / or degradative processes, which result in a decrease in therapeutic activity. International application WO 2023 / 218391 describes an extraction technology based on natural eutectic solvents (NaDES), capable of preserving and concentrating the main phenolic compounds while reducing the use of organic solvents.
[0008] Despite the interest in olive oil polyphenols, there are currently no documented topical formulations that are well tolerated by the mucous membranes and skin and specifically designed to treat LSA.
[0009] There therefore remains a need to identify formulations that are effective in treating Lichen sclerosus et atrophicus (LSA) and well tolerated by the mucous membranes and skin.
[0010] SUMMARY OF THE INVENTION
[0011] Through extensive studies and trials, the Applicant has demonstrated the efficacy of formulations comprising a eutectic solvent extract of polyphenols from or derived from olive oil in the treatment of Lichen sclerosus et atrophicus (LSA). Furthermore, the Applicant has also found that the addition of one or more ingredients, such as resveratrol, tocopherols, and phytosterols, confers to the composition a concomitant anti-inflammatory, antioxidant, and skin barrier-protective effect. Such compositions may further comprise one or more ingredients that, for example, increase the stability of the composition itself and / or promote its gradual absorption, without, however, interfering with the integrity of mucosal lesions. The use of the compositions in any of the embodiments described herein is therefore associated with several advantages: the anti-inflammatory efficacy of the composition can reduce or replace the use of topical or systemic corticosteroids, possibly combined with
[0012] immunostimulants, resulting in an improved safety profile of the treatment protocol; furthermore, the simultaneous immunomodulatory, antioxidant, and tissue-regenerating action meets the clinical needs of patients with LSA
[0013] The present invention therefore relates to a composition for topical use comprising an extract in a eutectic solvent of polyphenols from or derived from olive oil and resveratrol, optionally also comprising one or more ingredients selected from the group consisting of fatty acids, tocopherols, phytosterols, vitamins, and mixtures thereof, and / or extracts or oils containing them, and, finally, one or more pharmaceutically acceptable excipients. Furthermore, the present invention relates to devices comprising said composition. Finally, the composition for use as a medicament and the specific uses thereof are further embodiments of the invention.
[0014] GLOSSARY
[0015] Unless otherwise defined, the scientific and technical terms used in this description in connection with the present invention shall have the meanings commonly understood by those skilled in the art. Furthermore, unless the context otherwise requires, terms in the singular shall include the plural, and terms in the plural shall include the singular. In general, the nomenclature used in connection with, and the techniques of chemistry, formulation, medicine, etc., described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally carried out according to conventional methods well known in the art and / or as described in various general and more specific references that may be cited and discussed throughout this description, unless otherwise indicated.
[0016] Unless otherwise specified, as in the case of “eutectic solvent extracts,” the term “extract” refers to any product derived from biomass of botanical or bacterial origin, including all products resulting from mechanical processing (pulverization, grinding, mixing, pressing, and / or other methods) or from extraction processes (solvent extraction, distillation, maceration, and / or other specific methods) performed on such biomass, including mother tincturesand / or essential oils and / or oils.
[0017] In the context of the present invention, the term “eutectic solvent extract of polyphenols from or derived from olive oil” refers to an extract as described in International Patent Application WO 2023 / 218391; said document is incorporated by reference into this application.
[0018] In the context of the present invention, the terms “eutectic solvent” or “deep eutectic solvent” (DES) refers to a solvent composed of two or more components, specifically at least one hydrogen bond acceptor (HBA) and one hydrogen bond donor (HBD) that interact with each other by self-associating and forming a eutectic mixture with a melting temperature much lower than that of its components. It is hypothesized that self-association occurs through hydrogen bonding interactions, although it is presumed that Van der Waals forces may also play a significant role. The DES mentioned in this description and in the claims are also known in the industry as “low-transition-temperature mixtures” (LTTM). Unlike conventional solvents, such as ethanol, methanol, etc., deep eutectic solvents are non-volatile, meaning they have a very low vapor pressure and are therefore difficult to ignite. The toxicity of eutectic solvents is very low, their biodegradability is high, and the precursors required for their production are generally inexpensive, readily and abundantly available, and renewable.
[0019] In the context of the present invention, the term “natural deep eutectic solvent,” abbreviated as NaDES, refers to a eutectic solvent obtainable from precursors derived from natural sources, such as, for example, carbohydrates, organic acids, polyols, sugars, or amino acids.
[0020] In the context of the present invention, the term “betaine” refers to the compound N,N,N-trimethylglycine, unless otherwise indicated.
[0021] In the context of the invention, the term “eutectic solvent extract” refers to a polyphenol extract from or derived from olive oil obtained by using a eutectic solvent in accordance with any of the embodiments described herein as an extraction solvent. According to a preferred aspect of the invention, the term “eutectic solvent extract” specifically refers to an extract of polyphenols from orderived from olive oil using a eutectic solvent as the extraction solvent via a process according to any of the embodiments as defined in this description and in the claims.
[0022] Throughout this description and the claims, the term “comprising” may be replaced by “consisting of”.
[0023] BRIEF DESCRIPTION OF FIGURES
[0024] Figure 1 illustrates the process for preparing the composition according to a preferred embodiment of the invention.
[0025] Figure 2 illustrates the use of the composition according to a preferred embodiment of the invention.
[0026] DETAILED DESCRIPTION
[0027] As mentioned above, the present invention relates to a composition comprising a eutectic solvent extract of polyphenols from or derived from olive oil and resveratrol.
[0028] According to any of the embodiments described herein, said eutectic solvent is any natural deep eutectic solvent (NaDES) known in the art.
[0029] A eutectic solvent suitable for use as an extraction solvent in the preparation of the extract included in the compositions described herein is a solvent that is stable and transparent at room temperature, i.e., a solvent that can be stored for long periods at room temperature without undergoing significant aggregation or crystallization. Such a solvent may comprise two or more compounds selected from hydrogen-bond acceptor compounds and hydrogen-bond donor compounds known in the art. Said eutectic solvent may comprise two, three, four, five, six, seven, eight, nine, or more components selected from hydrogen-bond acceptor compounds and hydrogen-bond donor compounds known in the art; preferably two or three components.
[0030] According to any of the embodiments described herein, said eutectic solvent comprises at least one hydrogen-bond acceptor compound selected from the group consisting of choline, betaine, proline, acetylcholine, urea,thiourea, methylurea, dimethylurea, trifluoromethylurea, carnitine, ethylammonium chloride, diethylammonium chloride, acetamide, trifluoroacetamide, and their salts or derivatives, and at least one hydrogenbonding donor compound selected from the group consisting of sugars (in particular glucose, fructose, sucrose, maltose, dextrose, ribose, galactose), amino acids (in particular proline, serine, glycine, alanine, glutamic acid), carboxylic acids (in particular malic acid, lactic acid, tartaric acid, benzoic acid, itaconic acid, citric acid, isocitric acid, caffeic acid, adipic acid), polyols (in particular glycerol, 1 ,2-propanediol, 1 ,3-propanediol, inositol, butanediol, ethylene glycol, triethylene glycol, sorbitol, xylitol, ribitol), and amines and their salts or derivatives
[0031] According to any of the embodiments described herein, said at least one hydrogen-bond acceptor compound and said at least one hydrogen-bond donor compound are present in said eutectic solvent in a molar ratio ranging from 10:1 to 1:10. In particular, said eutectic solvent may comprise at least one hydrogen-bond acceptor compound and at least one hydrogen-bond donor compound in a molar ratio of: 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1 , 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 (mokmol), preferably in a molar ratio of 1:1.5 or 1:1.8 or 1:2.2 or 1:3 or 1:3.2 or 1:4
[0032] According to any of the embodiments described herein, said eutectic solvent is a binary mixture consisting of a hydrogen-bond acceptor compound, preferably betaine or proline, and a hydrogen-bond donor compound, preferably glycerol or propanediol, in any of the forms described herein. Preferably, said eutectic solvent is a NaDES comprising or consisting of propanediol and betaine, more preferably 1 ,2-propanediol and betaine or 1 ,3-propanediol and betaine. Typically, the molar ratio of betaine to propanediol is between 1:1 and 1:4; preferably, it is 1:1.5.
[0033] The presence of NaDES in the extract comprised in the composition of the invention is particularly advantageous because it protects the heat-labile compounds comprised in the composition (such as for example oleocanthal, oleuropein aglycone, hydroxytyrosol, and resveratrol), thereby improving theirresistance to oxidation and degradation in a topical environment.
[0034] As previously mentioned, the polyphenols present in the eutectic solvent extract are naturally occurring polyphenols and, specifically, polyphenols from or derived from olive oil. Preferably, the olive oil is produced from olives obtained from plants of the species Olea europaea, Arbequina, Hojiblanca, Lechin, Manzanilla, Picual, and / or Verdial, preferably from olives of Olea europaea. Even more preferably, the olive oil is obtained from a cultivar particularly rich in polyphenols, such as Coratina, Frantoio, or Ogliarola, using any of the techniques known to a person skilled in the art. In any embodiment, said olive oil is virgin olive oil or extra-virgin olive oil. In one embodiment, the polyphenols present in the eutectic solvent extract comprise one or more compounds selected from simple phenols (tyrosol, hydroxytyrosol), secoiridoids (oleocanthal, oleacein, oleuropein aglycone), and their respective glycosides (ligstroside, oleuropein), flavonoids and lignans (apigenin, luteolin, and pinoresinol), or mixtures thereof; preferably, the eutectic solvent extract comprises, as the polyphenolic fraction, the following compounds: oleuropein aglycone, oleocanthal, and hydroxytyrosol.
[0035] According to any embodiment of the invention, the polyphenols present in the extract as defined above are present in the extract in an amount ranging from 1 to 200 mg / mL. The polyphenol content in the extract can be determined either by a colorimetric method (e.g., Folin-Ciocalteau) or by chromatographic analysis (e.g., reverse-phase UHPLC with spectrophotometric and mass spectrometric detectors). Preferably, the eutectic solvent extract comprises from 0.1 to 5 mg / mL of hydroxytyrosol, more preferably 2 mg / mL, and / or from 3 to 7 mg / mL of oleocanthal, more preferably 5 mg / mL, and / or from 1 to 4 mg / mL of oleuropein aglycone, more preferably 3 mg / mL; the content of the individual polyphenols is determined by colorimetric analysis (Folin-Ciocalteau) for total content, and confirmed for specificity and accuracy by UHPLC with spectrophotometric and mass detectors.
[0036] The present invention therefore relates to a composition comprising a eutectic solvent extract of polyphenols from or derived from olive oil and
[0037] resveratrol, wherein the eutectic solvent comprises betaine and propanediol, and the polyphenols are oleuropein aglycone, oleocanthal, and hydroxytyrosol. Said extract, comprising betaine, propanediol, oleuropein aglycone, oleocanthal, and hydroxytyrosol, is also defined in the present description as a stabilized polyphenolic complex (CMP)
[0038] According to any of the embodiments described herein, the resveratrol present in the composition may be selected from any commercially available resveratrol; preferably, the resveratrol may be of natural origin — that is, obtained by extraction and / or purification from a biomass containing it — of semisynthetic origin, or of synthetic origin. Resveratrol may be present in the composition in the form of an extract comprising it; by way of example and without limitation, extracts containing resveratrol may be extracts of Vitis spp., preferably Vitis vinifera.
[0039] According to any of the embodiments described herein, the weight ratio between the eutectic solvent extract of polyphenols from or derived from olive oil and resveratrol ranges from 1000:1 to 1000:5; preferably, the weight ratio between said extract and resveratrol is 1000:3.
[0040] The simultaneous presence in the composition of the eutectic solvent extract — also known as a stabilized polyphenolic complex (CMP) — and resveratrol is particularly beneficial: in fact, the presence of resveratrol synergistically enhances the antioxidant action of the stabilized polyphenolic complex, for example, by neutralizing (scavenging) free radicals, counteracting oxidative damage in injured tissues, and protecting membrane lipids from peroxidation, while also enhancing its anti-inflammatory action by modulating COX-1, COX-2, and NF-KB, thereby reducing the release of pro-inflammatory cytokines (TNF-a, IL-6). Furthermore, resveratrol contributes to the stabilization of the extract in a eutectic solvent, for example, by helping to prevent the oxidation of the polyphenols it contains.
[0041] According to any embodiment, the weight percentage of the eutectic solvent extract and resveratrol — defined as the sum of the individual weights of the eutectic solvent extract and resveratrol — is comprised in the range of 5-15% w / w based on the weight of the entire composition; preferably, 10% w / w based on the weight of the entire composition.
[0042] According to any embodiment, the composition comprises one or more ingredients selected from the group consisting of fatty acids, tocopherols, phytosterols, vitamins, and mixtures thereof, and / or extracts or oils containing them.
[0043] Typically, the fatty acids present in any of the compositions described herein may be selected from known and commercially available fatty acids; preferably, the fatty acids are natural or synthetic fatty acids; more preferably, natural. In particular, the fatty acids may be present in the composition in the form of extracts or oils, preferably oils, that contain them. For example, the fatty acids are selected from the group consisting of linoleic acid, linolenic acid, omega-3, also known as Vitamin F, and mixtures thereof; preferably linoleic acid, linolenic acid, omega-3, and mixtures thereof.
[0044] Typically, said extracts or oils may be selected from any of the commercially available extracts or oils known to contain one or more ingredients selected from the group consisting of fatty acids, tocopherols, phytosterols, vitamins, and mixtures thereof. Preferably, said extracts or oils are selected from the group consisting of Triticum vulgare oil, also known as wheat oil, Linum usitatissimum oil, also known as linseed oil, Helianthus annuus (sunflower) oil, Simmondsia chinensis (jojoba) oil, Borago officinalis (borage) oil, Oenothera biennis (evening primrose) oil, Persea americana (avocado) oil, Prunus amygdalus (sweet almond) oil, olive oil, and mixtures thereof; more preferably, wheat oil, flaxseed oil, and mixtures thereof.
[0045] Therefore, according to any of the embodiments described herein, the composition also comprises wheat oil, preferably wheat germ oil. Typically, wheat oil, preferably wheat germ oil, comprises fatty acids, preferably linolenic acid and linoleic acid, tocopherols, and phytosterols.
[0046] According to any of the embodiments described herein, the composition comprises a weight percentage of wheat oil, as defined above, ranging from 25% to 50% by weight of the total composition; preferably, ranging from 25% to30% by weight of the total composition; more preferably, 28% by weight of the total composition.
[0047] The presence of wheat germ oil in the formulation is beneficial: this oil, having emollient and regenerating properties, reduces local irritation, restores the skin’s lipid barrier, and promotes tissue regeneration. Furthermore, this oil also acts as a carrier substance (lipid carrier), improving the local diffusion, penetration, and topical absorption of polyphenols and resveratrol. In addition, this extract helps stabilize the polyphenols present in the formulation.
[0048] According to any of the embodiments described herein, the composition also comprises linseed oil, preferably flaxseed oil.
[0049] Typically, linseed oil, preferably flaxseed oil, comprises Vitamin F, also known as Omega-3; this vitamin consists of a mixture of fatty acids, preferably a-linolenic acid (co-3) and linoleic acid (co-6). In varieties with a high Omega-3 (HL) content, a-linolenic acid typically accounts for about 52% of the total lipid content, while linoleic acid is present in concentrations of around 17%. Other fatty acids present in smaller quantities include oleic acid (~20%), palmitic acid (~7%), and stearic acid (~4%). These percentages are confirmed by technical data reported in composition charts for linseed oils with high and low omega-3 content (e.g., Solin variety).
[0050] According to any of the embodiments described herein, the composition comprises a weight percentage of linseed oil, as defined above, ranging from 5% to 15% by weight of the total composition; preferably, 8% by weight of the total composition.
[0051] The presence of linseed oil in the composition is beneficial: in fact, this oil, and in particular the vitamin F it contains, competes with arachidonic acid, reducing and / or counteracting the synthesis of pro-inflammatory eicosanoids, and providing polyunsaturated fatty acids (linolenic and linoleic acids) that help maintain a proper balance in the hydrolipidic film. Furthermore, it exhibits synergistic effects, as demonstrated by in vitro and in vivo studies showing a significant reduction in levels of inflammatory cytokines (e.g., TNF-a, IL-6, COX-2) when polyunsaturated fatty acids (particularly ALA) and polyphenols areadministered in combination, compared to the use of individual agents. For example, combination treatments have shown a reduction of up to 40-60% in the inflammatory response compared to controls in models of skin inflammation, confirming the anti-inflammatory action of the formulation. These effects suggest a synergistic interaction between the metabolic pathways of omega-3s and phenolic compounds, with a positive impact on the modulation of oxidative balance and the barrier function of the epithelium, reducing the irritation and dryness typical of Lichen Sclerosus et Atrophicus.
[0052] Typically, the tocopherols present in any of the compositions described herein may be selected from known and commercially available tocopherols; preferably, the tocopherols are natural or synthetic tocopherols. The tocopherols may be present as such (e.g., tocopherol) and / or in the form of extracts or oils, preferably oils, containing them. According to any of the embodiments described herein, the tocopherols are selected from the group consisting of tocopherol, also known as Vitamin E, tocopherol esters, preferably tocopherol acetate, tocopherol succinate, tocopherol nicotinate, tocopherol linoleate, tocotrienols, phytotocopherols extracted from vegetable oils (e.g., wheat germ oil, sunflower oil, palm oil), and mixtures thereof; preferably, tocopherol esters; more preferably, tocopherol esters selected from tocopherol acetate, tocopherol succinate, tocopherol nicotinate, and mixtures thereof; more preferably, tocopherol acetate.
[0053] According to any of the embodiments described herein, the composition comprises a weight percentage of tocopherol, as defined above, ranging from 2% to 10% by weight of the total composition; preferably, 5% by weight of the total composition.
[0054] The presence of tocopherol in the composition is beneficial: in fact, tocopherol exerts a primary antioxidant action, helping to protect cell membranes from free radicals and supporting skin elasticity. Furthermore, it protects the lipid fraction (fatty acids) present in the composition from oxidation and rancidity, thereby extending the composition’s shelf life.
[0055] According to any of the embodiments described herein, the compositionmay include additional active ingredients, preferably in the form of botanical extracts, known to have a soothing effect. By way of example and without limitation, the composition may include one or more extracts of Aloe barbadensis (aloe vera), Calendula officinalis (calendula), Chamomilla recutita (chamomile), Malva sylvestris (mallow), Althaea officinalis (marshmallow), Tilia cordata (linden), Hamamelis virginiana (witch hazel), Symphytum officinale (comfrey), Plantago lanceolata (ribwort plantain), Glycyrrhiza glabra (licorice), and mixtures thereof; preferably aloe vera, calendula, and mixtures thereof. These botanical extracts are, optionally, included in the composition in a percentage by weight not exceeding 2% w / w of the total composition.
[0056] According to any of the embodiments described herein, the composition comprises water. Preferably, the composition comprises a water content by weight in the range of 20-40% w / w of the total composition; more preferably, in the range of 25-30% w / w of the total composition; more preferably 27%.
[0057] In none of the embodiments described herein, the composition contain organic solvents.
[0058] The absence of organic solvents, which are known to be harsh on the skin and mucous membranes, and the presence of emollient ingredients make this formulation suitable for prolonged use, even on compromised skin.
[0059] According to any of the embodiments described herein, the composition comprises one or more pharmaceutically acceptable, and preferably dermatologically acceptable, excipients or carriers. Pharmaceutically acceptable carriers or excipients are well known in the art and may be selected based on the intended use of the composition. Any additional components necessary for the formulation of such compositions may be selected by a person skilled in the art based on known techniques. By way of example and without limitation, such excipients are selected from the group consisting of preservatives, emulsifiers, wetting agents, lubricants, surfactants, thickeners, gelling agents, essential oils, colorants, antioxidants, humectants, chelating agents, pH regulators, rheological stabilizers, film-forming agents, dispersants, and mixtures thereof.
[0060] According to any of the embodiments described herein, the compositionmay comprise two, three, four, five, six, seven, eight, nine, ten, or more excipients. The weight percentages of the various excipients may be equal or different from one another.
[0061] According to any of the embodiments described herein, the emulsifiers may be selected from known and commercially available emulsifiers. Typically, the emulsifiers may be ionic or non-ionic emulsifiers. Preferably, the emulsifiers are selected from the group consisting of glyceryl monostearate, more preferably glyceryl monostearate SE, cetearyl alcohol, polyethylene glycol esters, more preferably PEG-8 esters with C12-C20 acids, polyglyceryl-3 polyricinoleate, lecithin, sorbitan esters (e.g., sorbitan oleate, sorbitan stearate), ceteth-20, steareth-21, polyglyceryl-6 distearate, lauryl glucoside, decyl glucoside, and mixtures thereof. Even more preferably, the emulsifiers are a mixture of glyceryl monostearate SE, cetearyl alcohol, polyglyceryl-3 polyricinoleate, and PEG-8 esters of C12-C20 acids.
[0062] According to any of the embodiments described herein, the total weight percentage of emulsifiers present in the composition ranges from 6% to 40% by weight of the total composition; preferably, 12% to 23% by weight of the total composition.
[0063] Preferably, the weight percentage of glyceryl monostearate SE is in the range of 2-10% w / w of the total composition; more preferably, 3-5% w / w of the total composition.
[0064] Preferably, the weight percentage of cetearyl alcohol is in the range of 2-10% w / w of the total composition; more preferably, 3-5% w / w of the total composition.
[0065] Preferably, the weight percentage of PEG-8 esters with C12-C20 acids is in the range of 1-10% w / w based on the weight of the entire composition; more preferably, 5-10% w / w based on the weight of the entire composition.
[0066] Preferably, the weight percentage of polyglyceryl-3 polyricinoleate is in the range of 1-10% w / w based on the weight of the entire composition; more preferably, 1-3% w / w based on the weight of the entire composition.
[0067] The presence of emulsifiers in the composition is beneficial: these
[0068] excipients enhance the formulation’s adhesion to the skin or mucosal surface, thereby improving the bioavailability of the active ingredients. When water is present, these excipients create and stabilize the oil-in-water (O / W) emulsion by reducing the interfacial tension between the oil and water phases. Furthermore, they regulate the viscosity and texture of the formulation, giving it, for example, a creamy or gel-like consistency. Additionally, these excipients contribute to the overall stability of the formulation and promote gradual absorption without interfering with the integrity of mucosal lesions.
[0069] According to any of the embodiments described here, preservatives may be selected from among those that are well-known and commercially available. Preferably, the preservatives are selected from the group consisting of glycerin, sorbic acid, salicylic acid, benzyl alcohol, phenoxyethanol, ethylhexylglycerin, sodium benzoate, dehydroacetic acid, gluconolactone, caprylyl glycol, piroctone olamine, and mixtures thereof; more preferably, the preservatives are present as a mixture of glycerin, sorbic acid, salicylic acid, and benzyl alcohol.
[0070] According to any of the embodiments described herein, the total weight percentage of preservatives is no more than 1% w / w of the total composition weight, preferably within the range of 0.20-1% w / w of the total composition weight; more preferably 0.20% w / w of the total composition weight.
[0071] The presence of preservatives in the composition is beneficial: in fact, glycerin, as a humectant, improves the formulation’s retention on the skin, while sorbic acid, salicylic acid, and benzyl alcohol act as preservatives and protect against microbial contamination, ensuring the product remains safe over time.
[0072] According to any of the embodiments described herein, the composition may include a gelling agent selected from those that are known and commercially available. Preferably, the gelling agent may be selected from the group consisting of carbomer, xanthan gum, guar gum, tara gum, gum arabic, alginates, carrageenans, microcrystalline cellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), sodium carboxymethylcellulose (CMC), cross-linked polyacrylates, polyvinylpyrrolidone (PVP), and mixtures thereof; more preferably, the gelling agent is carbomer, xanthan gum, or mixturesthereof.
[0073] According to any of the embodiments described herein, the composition has a pH compatible with the skin and / or mucous membranes; preferably, the composition has a pH in the range of 5.5 to 6.5.
[0074] According to any of the embodiments described here, the composition has a density ranging from 5,000 to 15,000 cPs, measured at 25°C using a rotational viscometer.
[0075] Accelerated aging tests (e.g., 40°C for 30 days) demonstrate physicochemical stability parameters consistent with the microbiological safety and integrity of the formulation: stable pH of 5.13 ±0.06, water activity (Aw) of 0.864 ±0.069, and absence of detectable microbial contamination (including Salmonella spp., Listeria monocytogenes, E. coli, Staphylococcus aureus, Enterobacteriaceae, and sulfite-reducing bacteria), according to UNI EN ISO methods. These results confirm the stability of the formulation even under thermal stress conditions, due to the synergistic action of NaDES, tocopherol, and essential fatty acids.
[0076] In light of the foregoing, the present invention relates to a composition comprising a eutectic solvent extract of polyphenols from or derived from olive oil and resveratrol, wheat germ oil, flaxseed oil, tocopherol, water, and one or more pharmaceutically acceptable excipients or carriers, as defined above.
[0077] The composition developed by the Applicant, as highlighted in this description, therefore possesses a combined (multimodal) anti-inflammatory, antioxidant, and skin barrier-protective action, resulting from the synergistically effective combination of the eutectic solvent extract and resveratrol, wheat oil, linseed oil, tocopherol, and the various excipients, as defined above. With regard to the anti-inflammatory effect, this effect is achieved because the polyphenols in olive oil (oleocanthal, hydroxytyrosol, oleuropein aglycone) and resveratrol inhibit the COX-2 / NF-KB signaling pathway, thereby reducing the production of pro-inflammatory cytokines (TNF-a, IL-6). Furthermore, fatty acids (Vitamin F) compete with arachidonic acid, reducing the synthesis of pro-inflammatory eicosanoids. Finally, wheat germ oil and vitamin E provide asoothing and emollient effect, reducing irritation and local inflammation. The antioxidant action, as described above, is attributable to the stabilized phenolic complex (CMP) and resveratrol, which act as free radical scavengers, counteracting oxidative damage in injured tissues. Furthermore, vitamin E and the natural tocopherols present in wheat germ oil enhance antioxidant protection by stabilizing cellular structures. The restoration of the skin barrier is attributed to the combination of essential fatty acids, polyphenols, and tocopherols, which promotes the restructuring of the stratum corneum, increasing elasticity and reducing the scaling typical of Lichen Sclero-Atrophicus. Furthermore, the hydration provided by the aqueous phase and glycerin contributes to maintaining skin homeostasis and barrier function. The presence of fatty acids, vitamin E, and other nutrients supports the trophism of epithelial cells, helping to reduce atrophic or damaging phenomena. Furthermore, the creamy-gel-like consistency, specific viscosity, and absence of irritants in the formulation allow for safe use even on chronic or sensitive lesions.
[0078] According to any of the embodiments described herein, the composition is a topical composition.
[0079] According to any of the embodiments described herein, the composition may be in liquid, semi-liquid, or semi-solid form. Preferably, the composition may comprise one or more phases; for example, when in liquid form, the composition may comprise an aqueous phase and an oily phase; preferably, the aqueous phase comprises the eutectic solvent and resveratrol, preservatives, and water, while the oily phase comprises wheat oil, linseed oil, tocopherol, and emulsifiers. The ingredients in the phases may be present in any of the embodiments as defined above.
[0080] Preferably, the composition may be in the form of a cream, emulsion, oil-in-water emulsion (also known as an O / W emulsion), gel, foam, ointment, or spray.
[0081] The composition, in any of the forms described above, may also be contained in a device suitable for its storage and / or application.
[0082] Preferably, the composition is contained in a medical device suitable for its application, preferably for topical application, and more preferably for topical application to membranes and mucous membranes. Such a device may be selected from those known to those skilled in the art and commercially available. For example, medical devices comprising the composition are selected from the group consisting of patches, bandages, impregnated gauze, gynecological tampons, absorbent sponges, soft ovules, hydrogel masks, bioadhesive films, mucosal strips, and combinations thereof. Said medical device may contain within it the composition of the invention; furthermore, said medical device may be impregnated or coated, preferably completely or partially, with the composition.
[0083] The composition, in any of the forms described above, may be contained in any container suitable for its storage and / or dispensing. For example, such containers may be selected from any known and commercially available container that protects the composition from exposure to air and light. Preferably, said container may be selected from the group consisting of airless containers, protective tubes, opaque bottles with a metering dispenser, singledose syringes, twist-off capsules, barrier blisters, multilayer heat-sealed pouches, retractable sticks; preferably, airless containers and protective tubes.
[0084] The composition can be prepared using methods known to those skilled in the art. However, the Applicant has identified a particularly advantageous method for preparing the composition, as it allows for the production of a homogeneous, stable, and skin-compatible emulsion, even without the use of organic solvents. These advantages stem from specific optimized operating conditions, such as: temperature control (30-40°C) during mixing, the gradual and fractional addition of the oil phase to the aqueous phase (or vice versa), continued agitation until complete homogenization, and subsequent controlled cooling (25-28°C). These conditions are essential for stabilizing the oil-in-water (O / W) emulsion, preventing coalescence or phase separation, and ensuring uniform distribution of the CMP and other lipophilic and hydrophilic active ingredients in the final matrix. Furthermore, these parameters ensure thepreservation of the functional integrity of the polyphenols and the desired creamy-gel-like consistency for a comfortable topical application.
[0085] The present invention therefore also relates to a process for preparing the composition in any of the embodiments described herein.
[0086] Typically, said process comprises at least one step of mixing at least one oil phase and at least one aqueous phase.
[0087] According to any of the embodiments described herein, said mixing is carried out by gradually and fractionally adding the oil phase to the aqueous phase, preferably in at least 2-3 distinct portions, or vice versa, to form an emulsion, followed by maintaining the emulsion under agitation. Preferably, during the mixing of the two phases described above, the temperature is maintained within a range of 30-40°C. Preferably, agitation is continued until the two phases are completely homogenized, more preferably for a total time of approximately 60 minutes, of which at least 40 minutes with a turboemulsifier and 20 minutes under controlled agitation. Preferably, once the holding phase under agitation is complete, the mixture is cooled to 25-28°C, promoting the stabilization of the emulsion and the uniform incorporation of heat-sensitive active ingredients.
[0088] According to any of the embodiments described herein, the process includes a pH adjustment step; said adjustment involves, if necessary, adding lactic acid to the emulsion, citric acid, or buffer solutions, preferably selected from lactate, citrate, phosphate, and acetate buffers, in an amount sufficient to bring the pH of the emulsion to a value between 5.5 and 6.5.
[0089] According to any of the embodiments described herein, the process includes a step for preparing an oil phase; this step involves combining wheat oil, linseed oil, tocopherol, and emulsifiers, all as defined above, to form an oil mixture, followed by mixing said oil mixture until an oil phase is obtained; preferably a homogeneous one. Preferably, the mixing step involves heating the oil mixture to a temperature in the range of 30-40°C.
[0090] According to any of the embodiments described herein, the process includes a step of preparing an aqueous phase; said step involves combiningwater, emulsifiers, and preservatives, all as defined above, to form an aqueous mixture, followed by mixing said aqueous mixture until an aqueous solution is obtained, followed in turn by adding to said solution the stabilized polyphenolic complex (CMP) and resveratrol, and any cofactors, preferably selected from ascorbic acid, nicotinamide (vitamin B3), ferulic acid, panthenol, glutathione, or antioxidant-carrying polymers, to form an aqueous phase. Preferably, during said steps, the temperature is maintained in the range of 30-35°C.
[0091] According to any of the embodiments described here, the order in which the ingredients are added to produce the aforementioned phases is not important. Preferably, the aqueous phase can be prepared by adding the ingredients in the following order: water, then preservatives, preferably glycerin, sorbic acid, salicylic acid, and benzyl alcohol, then emulsifiers, preferably polyglyceryl-3 polyricinoleate, then CMP and resveratrol. Preferably, the oil phase can be prepared by adding the ingredients in the following order: wheat oil, then linseed oil, then tocopherol, then emulsifiers, preferably, in order, PEG-8 esters with C12-C20 acids, glyceryl monostearate SE, and cetearyl alcohol.
[0092] According to any of the embodiments described herein, the process of preparing a composition according to the invention comprises the following steps:
[0093] - placing wheat oil, linseed oil, tocopherol, and emulsifiers, all as defined above, in a container, preferably made of stainless steel, to form an oily mixture;
[0094] - heating said oily mixture to 35-40 °C with moderate stirring until a homogeneous lipid phase is obtained;
[0095] - placing water, preferably purified, preservatives, and emulsifiers, all as defined above, and mixing to form an aqueous mixture;
[0096] - maintaining the mixing under agitation at a temperature of 30-35 °C until an aqueous solution is obtained;
[0097] - adding the polyphenolic extract stabilized in NaDES (CMP) and resveratrol [and cofactors] to said aqueous solution;
[0098] - gradually adding the oil phase to the aqueous phase (or vice versa), maintaining the temperature within the range of 30-40 °C;
[0099] - stirring until an emulsion is obtained, preferably a homogeneous one, more preferably in the form of a cream or gel;
[0100] - cooling said emulsion and controlling the pH (5.5-6.5) and / or viscosity (generally 5,000-15,000 cPs at 25 °C).
[0101] According to any of the embodiments described herein, the process may further include a step of packaging the composition in a container suitable for storing it. Said step preferably involves filling suitable containers, preferably airless bottles or barrier-protected tubes. In said containers, the composition is stable, preferably the polyphenols and fatty acids comprised in the composition are stable, for up to 12 months from the date of packaging. For the sake of clarity, the term “stability” refers to the composition’s ability to maintain its chemical-physical, microbiological, and functional characteristics unchanged over time, including but not limited to:
[0102] pH within the range of 5.0-6.0
[0103] absence of phase separation, coalescence, or visible sedimentation absence of significant organoleptic changes (color, odor, texture) absence of microbiological contamination
[0104] retention of at least 80% of the initial content of active polyphenols and essential fatty acids, measured using validated methods (e.g., UHPLC, GC-MS, spectrophotometric titrations).
[0105] The present invention also relates to compositions obtainable from any of the embodiments of the process described herein.
[0106] As already stated above, the composition of the invention is useful in the treatment of LSA, i.e. , a dermatological condition.
[0107] The present invention therefore relates to a composition according to any of the embodiments described herein for use as a medicament; preferably, for use in the treatment and / or prevention of a dermatological condition; more preferably, of a dermatological condition of an inflammatory or autoimmune nature; even more preferably a dermatological condition selected from Lichen sclerosus et atrophicus, chronic dermatitis, and psoriasis.
[0108] According to any of the embodiments described herein, the
[0109] dermatological condition affects the skin and / or mucous membranes.
[0110] According to any of the embodiments described herein, the composition may be used in the treatment and / or prevention of symptoms associated with Lichen sclerosus et atrophicus; preferably, erythema, pruritus, or desquamation.
[0111] According to any of the embodiments described herein, the composition may be administered to any subject suffering from Lichen sclerosus et atrophicus (LSA), chronic dermatitis, or psoriasis.
[0112] According to any of the embodiments described herein, the composition is administered topically; preferably, it is applied to skin or mucous membrane areas. Said skin or mucosal areas may be any skin or mucosal area exhibiting lesions caused by Lichen Sclerosus et Atrophicus, chronic dermatitis, and psoriasis. For example, and without limitation, the genital area, preferably the vulvovaginal or penoscrotal areas.
[0113] According to any of the embodiments described herein, the composition may be applied once or more times a day, preferably twice a day. More preferably, the treatment lasts at least 4 weeks. A treatment lasting 4-24 weeks is most preferred; a 12-week treatment is even more preferred.
[0114] According to any of the embodiments described herein, the dose of the composition applied may range from 0.5 to 2 mL, preferably 1 mL, per lesion or affected area, such as that caused by LSA.
[0115] The present invention also relates to the composition, as defined above, for use in a method for treating and / or preventing the aforementioned conditions, which involves the following steps: cleansing the area to be treated, preferably with water or saline solution; drying the cleansed area, preferably by dabbing; and applying the composition of the invention, preferably in an amount of 1 mL. The area to be treated is the area affected by the condition, such as the skin or the vulvar area.
[0116] Typically, the above method may be repeated several times a day, preferably twice.
[0117] As highlighted in the Example section, the use of the composition of the invention by individuals with LSA not only confirmed the clinical efficacy of thecomposition, leading to a significant reduction in symptoms (itching, pain) and skin discomfort in the short-to-medium term, but has also demonstrated that the composition has a good safety profile compared to traditional topical steroids, with minimal incidence of irritation or adverse reactions. These effects are associated with a possible decrease in the frequency of relapses, as the antioxidant and reparative action appears to improve tissue resistance in the medium term.
[0118] As mentioned, the composition not only represents an alternative to the classic treatments for the dermatological conditions discussed above, but it can also be used in combination with them.
[0119] Accordingly, the present invention relates to the composition, according to any of the embodiments described, as an adjuvant in the treatment and / or prevention of a dermatological condition; more preferably, an inflammatory or autoimmune dermatological condition; and even more preferably, a dermatological condition selected from lichen sclerosus et atrophicus, chronic dermatitis, and psoriasis.
[0120] The present invention therefore relates to a combination of a composition according to the invention and at least one other compound, preferably a pharmaceutically active compound, for simultaneous, separate, or sequential use in the treatment and / or prevention of a dermatological condition; more preferably, an inflammatory or autoimmune dermatological condition; even more preferably a dermatological condition selected from lichen sclerosus et atrophicus, chronic dermatitis, and psoriasis. Said other compound may be selected by a person skilled in the art from among compounds suitable for the treatment of said conditions; preferably, it may be a corticosteroid and / or an immunosuppressant. The routes of administration for the composition containing the other compound may be the same or different; preferably, the composition is administered topically, while the other compound is administered topically, orally, or parenterally
[0121] Finally, the present invention relates to the use of the composition in any of the embodiments described herein as a cosmetic, preferably with antioxidantand / or emollient and / or soothing properties. Preferably, in its cosmetic use, the composition is intended for individuals who do not suffer from or have not been diagnosed with a dermatological condition.
[0122] EXAMPLES
[0123] Example 1 - Composition according to one of the embodiments of the invention
[0124]
[0125] Example 2 - Process for preparing an embodiment of the composition of the invention
[0126] 1. Mixing Sequence (Operational Example)
[0127] o Oil Phase (Phase 1)
[0128] 1. Weigh wheat germ oil (e.g., ~28%), flaxseed oil (Vitamin F) (8%), tocopheryl acetate (5%).
[0129] 2. Gradually add the emulsifiers / structuring agents (PEG-8 esters with C12-C20 acids in the desired amount within 5-10%, glyceryl monostearate SE, and cetearyl alcohol within 3-5% each).
[0130] 3. Heat to 30-40°C while stirring moderately until a homogeneous blend is obtained.
[0131] o Aqueous Phase (Phase 2)
[0132] 1. Weigh the water (e.g., ~27% if you want to stay in the middle of the 25-30% range).
[0133] 2. Dissolve the preservative blend (glycerin, sorbic acid, salicylic acid, and benzyl alcohol <0.20%) in it.
[0134] 3. Add Polyglyceryl-3-polyricinoleate (1-3%), maintaining the temperature around 30-35°C.
[0135] 4. Then incorporate the CMP + Resveratrol (10%) already stabilized in NaDES, continuing to stir.
[0136] o Emulsion Formation
[0137] 1. Slowly pour the aqueous phase into the oil phase (or vice versa, depending on equipment specifications), maintaining a temperature of 30-40°C.
[0138] 2. Use a low- to medium-speed mixer to promote the O / W emulsion.
[0139] 3. Continue stirring until the gel-like cream is homogeneous.
[0140] 4. Gradually cool to 25-28°C and check viscosity, pH, and final appearance.
[0141] 2. pH and Shelf Life Check
[0142] o pH: Typically between 5.5 and 6.5, the optimal range for the skin and mucous membranes.
[0143] o Stability: Accelerated aging tests (e.g., 40°C for 30 days) demonstrate good physicochemical stability, due to the synergistic action of NaDES, tocopherol, and essential fatty acids.
[0144] o Viscosity: Generally medium-high (approximately 5,000-15,000 cPs at 25°C), measured with a rotational viscometer. It may vary depending on the actual ratio between the oil phase and the aqueous phase.
[0145] 3. Packaging and Storage
[0146] o It is preferable to use airless containers or protective tubes, which reduce exposure to air and light, helping to preserve the antioxidant properties of CMP + resveratrol.
[0147] o Store at room temperature, away from direct light and heat sources. The recommended shelf life is 12-24 months after opening, based on specific stability tests.
[0148] Example 3 - Efficacy study of a composition according to the invention in with lichen Sclerosus et
[0149] The composition prepared in accordance with Example 2 was used on a sample of patients with genital Lichen sclerosus et atrophicus, including women (ages 12-81) and men (ages 21-81), with varying symptoms and seventy. The treatment involved topical application of the composition twice daily to the affected areas (specifically vulvovaginal or penoscrotal) for a period of 3 months.
[0150] 1. Parameters and Evaluation Methods
[0151] Evaluations were conducted before the start of treatment and at the end of treatment (3 months, twice daily).
[0152] Objective evaluations: using LC-OCT imaging, analyzing morphological parameters (hyperkeratosis, Ridges network, dermo-epidermal junction, inflammation, capillary dilation, acanthosis).
[0153] Subjective assessments:
[0154] VAS (Visual Analogue Scale): score from 0 (no symptoms) to 10 (maximum symptoms) for itching / pain.
[0155] DLQI (Dermatology Life Quality Index): from 0 to 30, to estimate the impact of the condition on quality of life.
[0156] 2. Main results
[0157] Female group:
[0158] VAS: mean score from 6.5 to 1.0 —> -84.6%; treatment thus led to a significant reduction in symptoms associated with LSA.
[0159] DLQI: average score from 8.3 to 1.1 — -86.7%; the treatment therefore led to a reduction in the symptoms associated with LSA.
[0160] LC-OCT:
[0161] Hyperkeratosis: -76.2%
[0162] Inflammation: -58.1%
[0163] Dermal-epidermal junction disruption: -57.1%
[0164] The treatment therefore led to a significant reduction in hyperkeratosis, inflammation, and alterations in the dermo-epidermal junction compared to thepre-treatment assessment; furthermore, at the end of treatment, a morphological improvement was observed in over 75% of patients for each parameter.
[0165] Male group:
[0166] VAS: from 6.8 to 0.4 — -94.1%; the treatment thus led to a significant reduction in symptoms associated with LSA.
[0167] DLQI: from 7.0 to 0.0 — -100%; the treatment thus led to a reduction in the symptoms associated with LSA.
[0168] 3. Qualitative Observations
[0169] Observations
[0170] Rapid subjective relief: In most cases, relief from itching and burning was felt within the second week of treatment.
[0171] Excellent tolerability: two patients reported mild initial burning that resolved on its own, without the need to discontinue treatment.
[0172] Comparison with topical corticosteroids: several patients reported comparable or superior efficacy without the typical side effects (e.g., skin thinning).
[0173] The clinical and instrumental data obtained confirm that the composition of the invention exhibits an extremely favorable efficacy and tolerability profile in the topical treatment of Lichen sclerosus et atrophicus, with significant morphological and symptomatic benefits, without the use of topical steroids.
Claims
CLAIMS1. Composition for topical use comprising a eutectic solvent extract of polyphenols of or derivatives of olive oil and resveratrol.
2. Composition according to claim 1, wherein the weight / weight ratio between said eutectic solvent extract of polyphenols of or derivatives of olive oil and resveratrol ranges from 1000:1 and 1000:5.
3. Composition according to claims 1 or 2, comprising one or more ingredients selected from the group consisting of fatty acids, tocopherols, phytosterols, vitamins, and mixtures thereof and / or extracts or oils comprising thereof.
4. Composition according to claim 3, wherein said extracts or oils are selected from the group consisting of wheat oil, linseed oil, sunflower oil, jojoba oil, borage oil, evening primrose oil, avocado oil, sweet almond oil, olive oil, and mixtures thereof; preferably wheat oil, linseed oil, and mixtures thereof.
5. Composition according to claims 3 or 4, wherein said tocopherols are selected from the group consisting of tocopherol, tocopherol esters, tocotrienol, phytotocopherols from vegetable oil, preferably from sunflower oil, wheat oil, palm oil and mixtures thereof.
6. Composition according to any one of the previous claims comprising one or more pharmaceutically acceptable excipients or vehicles; preferably in form of cream, emulsion, oil / water emulsion, gel, foam, ointment, salve, spray.
7. Composition according to any one of the previous claims wherein said polyphenols comprise oleuropein aglycone, oleocanthal and hydroxytyrosol and said eutectic solvent comprises betaine and propandiol.
8. Composition according to any one of the previous claims for use as medicament or adjuvant.
9. Composition for use according to claim 8 for use in the treatment and / or prevention of dermatological pathologies; preferably with inflammatory or autoimmune character; more preferably selected from lichen sclerosus, chronic dermatitis and psoriasis.
10. Composition according to any one of the claims 1 to 7 for use in the prevention and / or treatment of chronic inflammatory disease of skin and mucosae lichen sclerosus.
